ArticleFrontiers in cell and developmental biology2026
Custom bipolar electrode for bleomycin-based electrochemotherapy in patient-derived uveal melanoma
Article in Frontiers in cell and developmental biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Uveal melanoma (UM) is a rare tumor entity and the predominant primary intraocular malignancy in adulthood. Despite high local tumor control rates, metastatic disease remains frequent and systemic therapeutic options are limited. Electrochemotherapy (ECT) with bleomycin enhances intracellular drug uptake through electroporation (EP), thereby increasing targeted antitumor activity. This study investigated the effects of bleomycin-based ECT delivered using a custom bipolar electrode in UM patient-derived xenografts (PDX). Methods: UM PDX were analyzed in both Results: ECT caused pronounced tumor disruption and decreased tumor size parameters compared with untreated controls, with statistically significant reductions in tumor area following EP at 750 V alone or combined with 2.5 μg/mL bleomycin and in tumor perimeter across all groups treated with EP at 750 V Discussion: Bleomycin-based ECT using a custom bipolar electrode induces substantial tumor damage in UM PDX
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.